THE LIFESCIENCES MAGAZINE

★ ★ ★

Pioneering Leader In NEURORESTORATIVE BIOTECHNOLOGY And Advanced Hydrogel Technologies, 2024

Global Events for Biotechnology and Nervous System Injury and Repair

Global E-Prescribing Market: Recent Developments

Stéphane Woerly

Founding President, Chief Scientific Officer, and Chief Medical Officer

NeuroBioMat

Leading Innovations in BIOTECHNOLOGY AND SPINAL CORD REPAIR

SUBSCRIBE

How about showcasing your products to
90,000+ C-suite Subscribers?
To get recent updates of our magazines

SUBSCRIBE US

THE LIFESCIENCES MAGAZINE
Global Healthcare BI Platform Market: Size, Share, Growth Trends, and Forecast by Function, Technology, Application, and Region (2024-2031)
Pioneering Leader Driving
INNOVATION AND GROWTH
in Healthcare and Biotech Industry
ISSA KILDANI
Principal Consultant
Ambrosia Ventures
Leading with
PASSION AND TRANSFORMING
HUMAN HEALTH

OUR PREVIOUS EDITIONS

The Lifesciences Magazine, 1985, Henderson Rd, Columbus, Ohio, 43220

Follow Us On:

For Editorial Concerns: editors@thelifesciencesmagazine.com
For Sales & Branding Enquiries: matthew@thelifesciencesmagazine.com
For Subscription: info@thelifesciencesmagazine.com

Publisher
The Lifesciences Magazine
Creative Content Editor
Shalmali W.
Marketing Coordinator (USA)
Matthew Eden
PR & Marketing Coordinator
Michael Stevens

Business Development Executive
Susan Wilson
Creative Designer
Paul Young
Social Media Manager
Amy Muller
Digital Circulation Manager
Amanda V.

This list is NOT a ranking. The companies on listed in magazine serve different aspects of the market, making ranking them in any order except revenue impossible and unfair. We try to bring a perfect platform for business organization to showcase their valued products/ services.

Copyrights © The Lifesciences Magazine All Rights Reserved. The images and content included in this magazine should not be copied, transferred or reproduced in any form or by any means, electronics, mechanical, photocopying, recording, otherwise, without proper permission from The Lifesciences Magazine. The Lifesciences Magazine solely owns all the reprint rights.

FROM EDITOR'S DESK

Welcome to this special edition of **The Lifesciences Magazine,** where we proudly present *"Pioneering Leaders in Neurorestorative Biotechnology and Advanced Hydrogel Technologies, 2024."* In this issue, we shine a spotlight on **Stéphane Woerly, Founding President, Chief Scientific Officer, and Chief Medical Officer of NeuroBioMat.** His extraordinary work is reshaping the landscape of medical treatment and making a profound impact on patients' lives.

In the realms of neurorestorative biotechnology and hydrogel technologies, leadership transcends mere innovation; it embodies a relentless commitment to improving health outcomes and transforming the patient experience. For over three decades, Stéphane has been at the forefront of this mission, revolutionizing hydrogel technology to address the critical challenges associated with spinal cord injuries. His innovative approaches have set new standards, positioning him as a key figure in advancing biotechnology and creating solutions to once-intractable medical challenges.

Hydrogels, with their unique ability to retain significant amounts of water while maintaining a stable 3D structure, hold immense potential in medical applications. Stéphane's pioneering work in this area exemplifies how scientific innovation can lead to tangible improvements in patient care. By developing advanced hydrogel technologies, he is not only enhancing treatment modalities but also paving the way for breakthroughs that could significantly improve the lives of those affected by spinal cord injuries.

Stéphane's journey is fueled by a passion for science and an unwavering dedication to making a difference. His vision and leadership at NeuroBioMat inspire a new generation of researchers and practitioners in the field, demonstrating that the intersection of technology and compassionate care can lead to remarkable advancements in healthcare.

We invite our readers to explore the transformative impact of Stéphane Woerly's work in this issue. His story serves as a testament to the power of innovative thinking and the profound difference it can make in the lives of individuals facing challenging health conditions. Let us celebrate his achievements and draw inspiration from his commitment to advancing the future of neurorestorative biotechnology.

Shalmali

Shalmali W.

REDEFINING THE SCIENCE OF LIFE

The Lifesciences Magazine is global healthcare solutions platform that paves the way for various healthcare innovations, advices of professionals.

THE LIFESCIENCES MAGAZINE

LEADERS IN SPOTLIGHT

On the cover of this issue, we proudly feature **Stéphane Woerly,** the **Founding President, Chief Scientific Officer, and Chief Medical Officer of NeuroBioMat.** With over three decades dedicated to advancing hydrogel technology, Stéphane is transforming treatments for spinal cord injuries, solidifying his position as a key figure in neurorestorative biotechnology.

Stéphane's academic foundation includes an MD from France and a PhD in Neuroscience from Canada. His career spans multiple countries, including the U.S., the UK, the Czech Republic, and France, where he has made significant contributions in both academic and corporate environments. Renowned for his work in polymer chemistry, he has focused on developing groundbreaking treatments for spinal cord injuries.

At the heart of Stéphane's innovation is his Neurogel Technology, a hydrogel-based scaffold that mimics the extracellular matrix (ECM) to support the regeneration of damaged nervous tissue. This critical advancement addresses the nervous system's limited self-repair capabilities, facilitating tissue regeneration in ways previously thought impossible.

Stéphane's interdisciplinary expertise combines neuroscience, polymer science, and experimental neurosurgery, driving novel approaches in neurorestoration. His extensive knowledge of hydrogel design and polymer-based medical devices has established him as a trailblazer in the field. Having previously served as a C-level executive at Organogel Canada Ltd., Stéphane continues to influence the biotechnology landscape.

"I believe in the power of innovative solutions to change lives," he states, reflecting his commitment to merging scientific discovery with compassionate care. Stéphane Woerly's leadership is reshaping the future of healthcare, making him a vital leader to watch in the industry.

CONTENTS

10. COVER STORY

Stéphane Woerly

18. ARTICLE

Neurorestorative Biotechnology: Revolutionizing Clinical Applications

22. MARKET RESEARCH REPORT

Global E-Prescribing Market Size, Share, Growth & Trends Analysis (2024-2031)

26. ARTICLE

Neural Tissue Engineering: Game Changers of Regenerative Medicine

30. GLOBAL EVENTS

Global Events for Biotechnology and Nervous System Injury and Repair

34. ARTICLE

Hydrogel-based Formulation Technology: A Breakthrough in Clinical Applications

38. NEWS OF THE WEEK

44. ARTICLE

Spinal Cord Repair: Advances and Challenges in Treating Spinal Injuries

SOME KIDS CAN'T
AFFORD

THE WIND IN THEIR HAIR

Donate
the joy
of riding
a bike.

cyclekids.org

STÉPHANE WOERLY

Leading Innovations in BIOTECHNOLOGY AND SPINAL CORD REPAIR

NeuroBioMat

Founding President, Chief Scientific Officer, and Chief Medical Officer

In neurorestorative biotechnology and advanced hydrogel technologies, leadership is about more than just innovation—it's about making a tangible difference in people's lives. Leaders in these sectors are pushing the boundaries of science, crafting cutting-edge solutions that transform the landscape of medical treatment. Their work not only addresses complex health challenges but also paves the way for breakthroughs that can revolutionize patient care.

Stéphane Woerly exemplifies this transformative leadership. As the **Founding President, Chief Scientific Officer, and Chief Medical Officer of NeuroBioMat,** Woerly has dedicated over three decades to revolutionizing hydrogel technology for spinal cord injuries. Hydrogels are cross-linked polymer networks that exhibit the ability to retain large amounts of water while maintaining their 3D structure and can achieve high porosity. His pioneering work has set new standards in the field, making him a key figure in advancing biotechnology and offering groundbreaking solutions to previously intractable medical challenges.

Pioneering Neurorestorative Innovations

Woerly holds an MD from France and a PhD in Neuroscience from Canada, where he spent nearly two decades, Woerly's professional journey spans Canada, the U.S., the UK, the Czech Republic, and France, reflecting significant contributions in both academic and corporate environments. Woerly is renowned for his work in polymer chemistry and hydrogels, particularly in developing treatments for spinal cord injuries. His Neurogel Technology, a hydrogel-based scaffold, is designed to support the regeneration of damaged nervous tissue by mimicking the extracellular matrix (ECM). In regenerative biology, ECM plays a critical role in regulating tissue repair and shaping organ architecture. This innovation addresses the nervous system's limited self-repair capabilities compared to other organs, providing a three-dimensional polymer network that facilitates tissue regeneration.

Woerly's interdisciplinary expertise, combining neuroscience, polymer science, and experimental neurosurgery, has driven novel neurorestorative approaches. His extensive knowledge in hydrogel design, free radical polymerization, and polymer-based medical devices has solidified his status as a trailblazer in the field. His entrepreneurial achievements include leading Organogel Canada Ltd. as a C-level executive for a decade, further establishing his influence in biotechnology.

In his leadership roles at NeuroBioMat, Woerly blends medical expertise with pioneering research in hydrogel technology. His MD and PhD credentials, coupled with hands-on experience in experimental neurosurgery during his training in Canada in experimental neurosurgery, provide him with a profound understanding of the challenges in repairing nervous system injuries.

Since 1986, Woerly has transitioned from working with natural polymers like collagen to synthetic hydrogels due to their inert nature and reduced immune response as well as the possibility of adjusting their physico-chemical properties and adding novel functionalities to the polymer network targeting neuronal biological functions. His fellowship with the Medical Research Council of Canada and studies at the Institute of Macromolecular Chemistry in Prague refined his skills in hydrogel design. Upon returning to Canada, Woerly advanced hydrogel systems with improved physical properties and geometry, reinforcing his role as a pioneer in neurorestorative science.

Revolutionizing Spinal Cord Regeneration

Woerly has concentrated on a critical challenge: tuning the physical and chemical properties of hydrogels to match the nervous system's biology for effective regeneration. His innovative approach focuses on axonal regeneration, angiogenesis, and the recruitment of endogenous stem cells to heal volumetric tissue defects. NeuroBioMat's hydrogel acts as an extracellular matrix, promoting the self-healing ability of the spinal cord and supporting long-term repair as it enables tissue remodeling. The key challenge is to restore the translesional spinal network and connectivity across the lesion. With extensive preclinical experience, Woerly's team has developed a hydrogel suitable for human applications, set for its first trials in 2025.

Given its patient-targeted specificity, NeuroBioMat'stechnology has received FDA Breakthrough Device Designation in 2022.

Woerly's expertise merges polymer chemistry with nervous system regeneration, providing a unique tissue engineering solution. Unlike temporary relief methods like neurostimulation and exoskeletons, Woerly's approach aims for permanent regeneration of both motor and sensory systems, as the most promising way to promote functional recovery in people with spinal cord injuries. While only two companies, NeuroBioMat and InVivo Therapeutics, are pursuing this type of solution, NeuroBioMat's non-degradable hydrogel stands out as a semi-solid system with a dynamic structure that allows it to adapt to cell dynamics during tissue repair. It supports longer-term tissue remodeling, essential for the lengthy spinal cord regeneration process, unlike rapidly absorbed biodegradable hydrogels. NeuroBioMat's hydrogel exhibits sufficient physicochemical and structural properties to support neuronal tissue regeneration.

Progress in Preclinical Trials

Woerly discussed the progress of NeuroBioMat’s neurorestorative technology. While the first human study is slated for 2025, the success stories to date come from extensive preclinical trials using spinal cord injury models in animals. These trials have involved both transection and compression models, which mimic human spinal cord injuries. Woerly highlighted a series of experiments conducted in Canada and the U.S., where NeuroBioMat's hydrogel was implanted into the spinal cords of animals.

These experiments, performed in collaboration with academic institutions like UCLA, the University of Kentucky, and the University of Alabama, showed promising results. Using techniques such as immunocytochemistry and behavioral studies, researchers observed significant regeneration of nerve fibers within the hydrogel. Additionally, the trials showed mobilization of endogenous stem cells, microvascularization, and partial recovery of locomotor functions.

Though not 100% recovery was achieved, Woerly emphasized that even a 10% regeneration of motor system axons could lead to significant improvements in patients' quality of life. The potential to restore minimal motor functions offers hope to individuals suffering from spinal cord injuries, whose lives are often marked by chronic pain and limited mobility.

The success of these preclinical trials, conducted over several years, has laid the foundation for human trials. NeuroBioMat is actively working with the FDA to prepare for the first-in-human study, which represents the next critical step toward bringing this neurorestorative technology to patients. Woerly's collaboration with leading neurosurgeons and academic institutions has ensured that the research has been rigorously tested and published, and NeuroBioMat remains focused on advancing its technology for human application.

Prioritizing NeuroRestorative Technology

Woerly explains how he prioritizes his research efforts across neurorestorative biotechnology and hydrogel technologies. Woerly emphasized the importance of focusing on technologies with high potential for success. He highlighted a market study conducted in Europe and the U.S., which revealed significant interest from neurosurgeons in NeuroBioMat’s hydrogel technology.

One key factor in the prioritization of this research is the simplicity of the hydrogel application. Neurosurgeons prefer straightforward technologies, particularly in operating rooms where time and ease of use are critical. NeuroBioMat’s hydrogel, designed specifically for spinal cord injuries, offers several attractive properties for surgeons. The gel, known as SPINEREP is bioadhesive, meaning it sticks immediately to neural tissue without the need for sutures. Additionally, it has hemostatic properties, helping to stop microbleeding, a common challenge in spinal cord surgeries, and maintaining a clear operating field. Furthermore, the polymer scaffold has elasticity and mechanical strength properties similar to the neural parenchyma, facilitating its surgical implantation and integration into spinal tissue.

Woerly’s focus on hydrogel technology stems from its ease of use and effectiveness. SPINEREP can be easily cut to fit the lesion cavity and, once applied, stays in place to help reconstitute the anatomical continuity of the spinal cord. While the current focus is on spinal cord injuries, Woerly noted that future research could extend this technology to brain injuries, requiring further study to explore its potential in reconstructing parts of the brain using hydrogel systems.

Future of NeuroRestorative Biotechnology

Woerly envisions significant advancements in neurorestorative biotechnology, particularly in the realm of hydrogel technologies by modifying the chemical structure of polymer networks to give them specific properties or enhance their performance. Thus, he sees the future focusing on chemically attaching growth factors, such as BDNF (Brain-Derived Neurotrophic Factor), to hydrogels to enhance their biocompatibility/biofunctionality couple within the nervous system. This approach could accelerate tissue regeneration and improve outcomes for patients suffering from neurological injuries.

Additionally, Woerly foresees the potential for combining hydrogels with stem cells to address volumetric tissue defects in the brain. This combination could prepare new tissue that could be transplanted into the brain or spinal cord, further expanding the capabilities of neurorestorative technology. The versatility of hydrogel technology allows it to be enhanced through advancements in polymer chemistry and biology, offering numerous possibilities for future applications.

ONCOLYMPICS

BREAKING RECORDS

AstraZeneca

المجلس الأعلى للمستشفيات الجامعية

Supreme Council of University Hospitals

NEURORESTORATIVE BIOTECHNOLOGY: Revolutionizing Clinical Applications

Neurorestorative biotechnology is a growing field with the potential to transform treatments for neurological disorders and injuries. This interdisciplinary science combines biology, engineering, and medical technology to restore and regenerate the nervous system's function. With applications in treating conditions such as stroke, traumatic brain injury, spinal cord injury, and neurodegenerative diseases like Parkinson's and Alzheimer's, neurorestorative biotechnology is paving the way for innovative, life-changing therapies. In this article, we explore the underlying principles of this biotechnology, current clinical applications, and future directions in the field.



Understanding Neurorestorative Biotechnology

The nervous system is extremely complex, performing numerous functions in the body, including physical performance, mental processes, and perception. The nervous system heals very little on its own after an injury. Traditionally, neurological injuries and disorders are treated symptomatically, that is to say, according to their manifestations or outward symptoms, rather than for their actual damage or lack of function. Neural Restoration Biotechnology seeks to change this paradigm by directly attacking pathologic injury, fostering regeneration, and augmenting healing.

These sciences include cellular repair, tissue engineering, and molecular therapies. Put simply, solutions provided must be in the direction of aiding the body to heal the nervous system or introduce new cells and structures that could help in lost functionalities. Techniques deployed are stem cell therapy, biomaterial scaffolding, and gene therapy to induce neuroregeneration.

Key Applications in Clinical Use

Neural Restoration Biotechnology is actively being applied in several areas of clinical practice, each designed to address specific neurological challenges. Let's look at a few key areas:

- **Spinal Cord Injury Treatment**

Injuries to the spinal cord cause paralysis because the nerve fibers damaged may not successfully send signals. Neural Restoration Biotechnology, particularly through stem cell therapy, has great potential for the generation of new neurons once transplanted into the site of injury. The biomaterial hydrogels are applied in scaffold engineering to promote cell regeneration and fixations in the damaged spinal cord. This kind of work is poised to reconstitute function and hence further facilitate nerve repair important landmark in the recovery process of spinal cords.

- **Stroke Rehabilitation**

Stroke is one of the leading causes of disability resulting from interrupted blood flow to the brain causing tissue damage. Neurorestoration biotechnology is the stroke rehabilitation advanced through stem cell usage, replacing killed neurons, and improving plasticity in the brain. Results of these different clinical trials administering stem cell therapies have shown the ability to restore improved motor function and capacity for cognitive ability in stroke patients. Combining novel therapies as mentioned above along with the more conventional rehabilitation treatments such as physical therapy will likely enable significant improvement in recovery outcomes and positively enhance the overall quality of life for stroke patients.

- **Parkinson's Disease Treatment**

Parkinson's disease is based on neurodegenerative loss of dopamine-producing neurons. The treatments in place are symptomatic management without neuronal loss replacement. Neural Restoration Biotechnology looks forward to replacing the lost neurons through cell-based therapy, particularly induced pluripotent stem cells. Such are undifferentiated cells that can easily differentiate into a dopamine-producing neuron and be placed into the brain, with the potential, to restore dopaminergic production for the possibility of offering a better approach to reverse the phenomenon of Parkinson's disease.

- **Alzheimer's Disease Research**

Alzheimer's disease poses significant challenges in understanding and treatment. Neural Restoration Biotechnology is investigating ways to regenerate neurons and introduce molecular therapies to slow cognitive decline. One promising approach is gene therapy, which aims to modify the expression of genes associated with Alzheimer's, potentially protecting brain cells from damage. Although these therapies remain experimental, Neural Restoration Biotechnology offers hope for developing more effective, disease-modifying treatments for this devastating neurodegenerative disorder.

Technological Advances Driving Neural Restoration Biotechnology

Several technological innovations are propelling the field of Neural Restoration Biotechnology forward, each playing a critical role in the success of these therapies.

1. **Stem Cell Technology**

At the center of Neural Restoration Biotechnology lies the stem cell. Since they can differentiate into more than one type of cell, they hold good promise to replace damaged neurons. Embryonic stem cells, mesenchymal stem cells, and iPSCs are some types under review for neurorestorative applications. Mass production and safe usage of these stem cells form a priority for further clinical application.

2. **Biomaterials and Tissue Engineering**

Another very important aspect is the creation of biocompatible materials. Biomaterials can also be used as scaffolds. Scaffolds provide a framework for developing and growing new cells of the nerves. It has so far been promising in the use of hydrogels, nanofibers, and biodegradable polymers, especially regarding minimizing scar formation by supporting the regeneration of nerves while thwarting recovery in spinal cord injuries.

3. **Gene Therapy**

It is focused on the genetic aspect of the pathogenesis of neurological diseases. Genes involved in neurodegenerative disorders are managed in Neural Restoration Biotechnology by gene editing techniques, such as CRISPR-Cas9. This means correcting genetic mutations associated with a disease, such as Huntington's or Alzheimer's. It could lead to long-term therapeutic effects.

4. **Advanced Imaging and Diagnostic Tools**

Imaging of real-time neuroregeneration is one exciting area under development. With advancements in MRI, PET scans, and other imaging technologies, clinicians can view the treatment's effects on the brain and nervous system, thus optimizing the therapy to provide a better outcome for the patient.

Future of Neurorestorative Biotechnology

Besides the concerns for the future, clinical practice offers much more in the form of discoveries through continued Neural Restoration Biotechnology research. The thrust of work now is toward combination therapies, not only to advance their effectiveness individually but indeed to make them more powerful and effective together. Thus, for example, combining stem cell therapy with gene editing could yield even more powerful treatments for complicated neurodegenerative diseases.

Soon enough, we shall see clinical applications of neurorestorative biotechnology beyond these first models open to other widespread diseases, such as traumatic brain injuries, multiple sclerosis, and amyotrophic lateral sclerosis. This, in turn, will spur a sort of degree of refinement towards personalized medicine approaches whereby therapies are better tailored and produced according to the genetic and molecular profiles of individual patients; therefore, maximally improving the precision and efficacy of their treatments.

Conclusion

Spinal Cord injuries, stroke, Parkinson's disease, and so on an endless list of conditions thought hitherto to be otherwise hopeless cases now have a new hope through the repair and regeneration of neural tissues. It is one of the newest and most rapidly evolving areas for potential revolutionary treatment in neurological disorders and injuries. As more knowledge is established, neurorestorative biotechnology is well-poised to be the hallmark of future clinical therapeutics in changing how a human brain should be approached for neurological care and recovery.

So~Safe®
Water Technologies

Don't let this heap grow

Switch to tap water
The ultimate solution

Santeo Mineral Water RO Purifier

Your own 7-Stage Mini Mineral Water Purifier with a flow capacity of 700 US Gallons Per Day

Global E-Prescribing Market Size, Share, Growth & Trends Analysis (2024-2031)

The global e-prescribing market is witnessing rapid growth, driven by technological advancements, regulatory support, and widespread adoption across healthcare systems. North America leads the market due to high electronic health records (EHR) usage and favorable legislation, while the Asia Pacific region is expanding quickly, boosted by increased healthcare spending and innovations. Key trends include enhanced EHR integration for real-time access to patient medication data and AI-driven tools to identify drug interactions and dosage errors.

Mobile health (mHealth) apps are transforming prescription management by enabling remote handling, improving workflow efficiency, and patient care. Regulatory initiatives like the Medicare Electronic Prescribing Incentive Program in the U.S. and Europe's Electronic Prescription Services further promote adoption by enhancing patient safety and standardizing practices. Companies like NextGen Healthcare, eClinicalWorks, Oracle (Cerner), and Allscripts are market leaders, though challenges like high implementation costs and the need for skilled personnel remain. Despite these hurdles, the market's growth trajectory is strong, reflecting continued integration of e-prescribing systems worldwide.

Table Of **Contents**

- Executive Summary
- Research Methodology
- Market Trends
- Market Assessment
- Impact of Recession on the Market
- Global E Prescribing Market, By Component
- Global E Prescribing Market, By Delivery Mode
- Global E Prescribing Market, By Substances
- Global E Prescribing Market, By Usage
- North America Market Analysis
- Europe Market Analysis
- Asia-Pacific Market Analysis
- Latin America and the Caribbean Market Analysis
- The Middle East and Africa Market Analysis
- Competitive Landscape
- Company Profiles

Global E-Prescribing Market: Key Growth Drivers

Technological Advancements

Technological innovation is a major driver in the e-prescribing market. Modern systems now offer integrated decision support, drug interaction alerts, and real-time access to patient data. These advancements improve prescription accuracy and efficiency, significantly reducing the risk of errors and enhancing patient safety.

Government Initiatives and Regulations

Government policies promoting digital health solutions play a critical role in market growth. Regulations like the 21st Century Cures Act in the U.S. require e-prescribing for controlled substances, accelerating adoption among healthcare providers. These initiatives streamline prescription workflows, improving patient care and driving wider market uptake.

Rising Chronic Disease Rates

The increasing prevalence of chronic conditions such as diabetes, hypertension, and cardiovascular diseases further fuels the growth of the e-prescribing market. These systems facilitate better medication management for chronic conditions, ensuring timely and accurate prescriptions, which leads to improved treatment adherence and outcomes for patients.

Global E-Prescribing Market: Opportunities

Emerging Markets Growth: Countries like India, China, and Brazil offer significant revenue potential as healthcare systems modernize and adopt e-prescribing solutions.

Mobile Health Advancements: The rise of mobile health (mHealth) apps for prescription management and medication tracking creates new opportunities to enhance patient engagement and expand services.

Focus on Safety and Error Reduction: Increased emphasis on patient safety and reducing medication errors drives demand for advanced e-prescribing systems with features like drug interaction alerts.

Global E-Prescribing Market: Recent Developments

March 2022

Cerner Corporation partnered with Nuance Communications to integrate AI-powered tools into Cerner's EHR system. This collaboration aimed to enhance prescribing accuracy, reduce errors, and streamline the prescription process through AI-driven insights.

June 2022

Surescripts launched CareEvent, a feature that offers real-time clinical updates and alerts for healthcare providers, improving efficiency and accuracy in medication prescribing.

February 2023

Epic Systems expanded its e-prescribing network into Europe, advancing global efforts to improve prescription safety and medication adherence across diverse healthcare systems.

Key Market Players:

Global E Prescribing Market features several key players that dominate the industry, including

- Allscripts Healthcare, LLC
- Athenahealth
- Change Healthcare
- DrFirst
- Epic Systems Corporation
- McKesson Corporation

FAQ

Who are the major players in the e-prescribing market?

Leading companies include Cerner, Epic Systems, Allscripts Healthcare Solutions, Surescripts, and NextGen Healthcare, which drive advancements in e-prescribing technology.

Which regions are growing the fastest?

Asia-Pacific is projected to have the highest growth rate through 2029, while North America currently leads the market due to strong government support and well-developed healthcare infrastructure.

What challenges does the market face?

Key challenges include high implementation and maintenance costs, workflow disruptions during adoption, and concerns about data security and patient privacy.

Dom, Solon High
Thursday 9:48 PM

Took out the trash.

Let’s be real.

It might seem like you’re missing out. In reality, only 19% of high school students in Cuyahoga County currently drink alcohol. Which means 81% don’t.

NEURAL TISSUE ENGINEERING: GAME CHANGERS OF REGENERATIVE MEDICINE



The neurological system plays a significant role in maintaining the functions of the human body. Its main role is to process and communicate sensory information to other parts and ensure the smooth functioning of the body.
Neurological problems disrupt the body and have severe aftermath results. The field of Neural Tissue Engineering (NTE) helps in the diagnosis of neurological problems. It mainly focuses on developing biological instruments and components to maintain and improve the neural functioning of the body. There is an increase in neurodegenerative diseases and healthcare officials are on the constant run to tackle them.

This article will discuss more on NTE's key components, its applications, importance, and challenges, and how they contribute to improving the healthcare sector.

What is Neural Tissue Engineering?

NTE is designing and developing machines or equipment that can support the growth, survival, and function of neural cells. The main goal of NTE is to create functional neural tissues that can replace or repair damaged neural circuits resulting from trauma, injury, or disease. This approach integrates biological, chemical, and engineering principles to develop scaffolds, biomaterials, and cell-based therapies for neural applications.

The Need for Neural Tissue Engineering

The increasing rate of neurological disorders, such as Alzheimer's, Parkinson's disease, spinal cord injuries, and stroke, showcases the need for effective treatment options. Traditional approaches, such as pharmacotherapy and surgical interventions, often fall short of promoting the true regeneration of neural tissues. NTE presents a promising alternative, aiming to restore not only the physical structure but also the functioning of neural tissues.

Current Challenges in Neurology

Despite advancements in the medical sector, the challenges in treating neurological conditions remain significant. Neural cells, particularly neurons, have a limited ability to regenerate. Injuries to the central nervous system (CNS) often lead to irreversible damage, causing permanent functional problems. Moreover, the complexity of neural networks and neurochemical environments complicate the development of effective therapies. NTE seeks to address these challenges by providing effective methods for neural regeneration.



KEY COMPONENTS

Neural tissue engineering involves several key components to improve the cell repair.
They are:

1. Scaffolds

Scaffolds serve as three-dimensional frameworks that provide structural support for cell attachment and growth. In neural tissue engineering, scaffolds are designed to replicate the extracellular matrix (ECM) found in native neural tissues. They can be composed of natural or synthetic materials, such as collagen, hyaluronic acid, and biodegradable polymers. The choice of scaffold material influences cell behavior, including proliferation, differentiation, and migration.

2. Biomaterials

Biomaterials play a crucial role in neural tissue development by providing the necessary biochemical signals that promote neural cell growth and differentiation. These materials are functioned with the help of bioactive molecules, such as neurotrophic factors, to enhance their efficiency. These factors can stimulate neuronal survival and axonal regeneration, and improve the overall success of the engineered neural tissue.

3. Cell Types

The selection of appropriate cell types is crucial for the success of neural tissue generation. Various cell sources can be utilized, including stem cells, induced pluripotent stem cells (iPSCs), and primary neural cells. Stem can split into various neural cell types. iPSCs, derived from adult cells, offer a promising avenue for patient-specific therapies, minimizing the risk of immune rejection.

4. Growth Factors

Growth factors are critical in promoting cellular activities in neural tissue generation. They facilitate neuronal survival, growth, and differentiation. Commonly used growth factors include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell-derived neurotrophic factor (GDNF). These factors from scaffolds can create a favorable microenvironment for neural regeneration.

Applications

The applications of neural tissue engineering are vast and varied.

1. Spinal Cord Injury Repair

Neural tissue engineering helps in repairing spinal cord injuries. By creating scaffolds that support axonal growth and repair the injury site, NTE can facilitate functional recovery. Studies have shown the ability to restore motor function in animal models through the implantation of engineered neural tissues.

2. Neurodegenerative Disease Treatment

NTE provides a platform for developing therapies aimed at neurodegenerative diseases such as Parkinson's and Alzheimer's. By creating neural grafts that produce essential neurotransmitters or neurotrophic factors, it may be possible to prevent the effects of these diseases and restore lost functions.

3. Peripheral Nerve Repair

In cases of peripheral nerve injury, NTE can be employed to create methods that guide regenerating axons to their target tissues. These methods can be combined with bioactive materials that enhance nerve regeneration and functional recovery.

4. Brain Repair and Regeneration

Emerging research in neural tissue engineering is exploring strategies for repairing damaged brain tissues. By utilizing stem cell-based therapies and engineered scaffolds, researchers aim to regenerate lost neuronal circuits and restore functions.

Future Perspectives

1. Personalized Medicine

Advancements in iPSC technology are paving the way for personalized neural tissue engineering. Patient-specific stem cells can be used to generate custom-engineered neural tissues, minimizing the risk of rejection and improving therapeutic outcomes. This personalized approach holds great potential for treating a variety of neurological disorders.

2. Combination Therapies

The future of NTE may involve the integration of multiple therapeutic modalities. Combining NTE with pharmacological interventions, gene therapy, and rehabilitation strategies could enhance the overall effectiveness of treatments for neurological conditions.

3. Regulatory Challenges

The potential of NTE is increasing. The regulatory challenges must be addressed to bring innovations to clinical practice. Establishing effective protocols for the manufacturing, testing, and application of engineered neural tissues is crucial to ensure their safety and efficiency.

4. Ethical Considerations

The field of neural tissue engineering raises important ethical questions, particularly regarding the use of stem cells and genetic modifications. Discussions about the ethical implications of these technologies will change the future of NTE and its applications.



Conclusion

The world has seen significant developmental changes across various fields. Technology and efficiency have increased, and along with them, there is a rise in major medical illnesses. The threatening ones are neurological diseases. They alter the whole functioning of the body, and in some cases lead to paralysis. Neural tissue engineering is coming up with innovative advancements to tackle challenging neurological problems. Implementing advanced engineering techniques and inventing biomedical machines has helped NTE to provide solutions to neurological disorders. With constant research and increased advancements, NTE is expected to increase the efficiency of diagnosing neural problems.

Kimora, Shaker Heights High
Saturday 7:35 PM

Ordered a burrito online.

Let's be real.

It might seem like you're missing out. In reality, less than 17% of high school students in Cuyahoga County currently use marijuana. Which means 83% don't.



19th International Conference on Advances in Biotechnology (ICAB 2025)

The 19th International Conference on Advances in Biotechnology (ICAB 2025) is a premier event aimed at uniting leading academic scientists, researchers, and industry professionals to exchange insights and share their latest research findings across various aspects of biotechnology. This interdisciplinary platform will foster discussions on recent innovations, trends, and challenges faced in the field, making it an invaluable opportunity for students, academics, and industry researchers alike to network and collaborate. Those interested in advancing their knowledge in biotechnology, as well as those looking to present original research, are encouraged to attend and contribute to this vital discourse.

Date: January 16-17, 2025 | Location: Montevideo, Uruguay

19th International Conference on Molecular Biology, Biochemistry and Biotechnology (ICMBBB 2025)

The 19th International Conference on Molecular Biology, Biochemistry and Biotechnology (ICMBBB 2025) is a premier event designed to unite leading academic scientists, researchers, and scholars to exchange experiences and research findings across all areas of Molecular Biology, Biochemistry, and Biotechnology. This interdisciplinary platform aims to foster discussions on recent innovations, trends, and practical challenges while offering opportunities for networking and collaboration. The conference invites contributions of research abstracts, papers, and e-posters, encouraging high-quality submissions that present original, unpublished results. This event is ideal for students, academics, industry researchers, and practitioners looking to enhance their knowledge and connect with experts in these dynamic fields.

Date: January 30-31, 2025 | Location: New York, United States



GLOBAL EVENTS FOR BIOTECHNOLOGY AND NERVOUS SYSTEM INJURY AND REPAIR

19th International Conference on Advances in Biotechnology (ICAB 2025)

The 19th International Conference on Biotechnology and Bioengineering (ICBB 2025) is a premier event dedicated to uniting leading academic scientists, researchers, and scholars to share and discuss their experiences and findings in the dynamic fields of biotechnology and bioengineering. This conference serves as an interdisciplinary platform for presenting the latest innovations, trends, and practical challenges, along with the solutions adopted within these domains. It welcomes contributions from prospective authors, encouraging submissions of original and unpublished research in the form of abstracts, papers, and e-posters. This event is ideal for students, academics, and industry professionals interested in advancing their knowledge and networks within biotechnology and bioengineering.

Date: March 03-04, 2025
Location: Taipei, Taiwan

18th International Conference on Bioscience, Biotechnology, and Biochemistry (ICBBB 2024)

The 18th International Conference on Bioscience, Biotechnology, and Biochemistry (ICBBB 2024) is a premier interdisciplinary platform aimed at uniting leading academic scientists, researchers, and scholars to share their experiences and research results in the fields of bioscience, biotechnology, and biochemistry. This conference not only fosters collaboration and discussion on recent innovations and trends but also addresses practical challenges and solutions in these dynamic disciplines. It invites contributions of original research abstracts, papers, and e-posters, making it an invaluable event for students, academics, and industry researchers eager to engage with cutting-edge developments. Those interested in the latest advancements in bioscience and biotechnology should definitely consider attending this enriching experience.

Date: November 25-26, 2024
Location: Buenos Aires, Argentina

The Central Nervous System Injury and Repair Gordon Research Conference

The Central Nervous System Injury and Repair Gordon Research Conference is a prestigious international event dedicated to exploring innovative research in spinal cord injury and regeneration. The conference focuses on bridging molecular insights with therapeutic innovation, addressing the complex challenges posed by CNS dysfunctions, particularly spinal cord injuries. Featuring cutting-edge presentations from leading scientists, the conference fosters collaboration and informal networking across all career stages through interactive discussions, poster sessions, and communal activities. The event is ideal for scientists, clinicians, industry professionals, and stakeholders passionate about advancing neuroprotective and neuroregenerative research.

Date: July 6-11, 2025
Location: Renaissance Tuscany IL Ciocco, Lucca (Barga), Italy

ROTTEN APPLE
On Stage!
Mi MOVIES
25¢
OOKS MAG
NOVELTIES
PEEP SHOW
2



We were into
health
when New York
wasn't.

NEW YORK FESTIVALS

HEALTHAWARDS

AWARDING
HEALTH SINCE 1957

Hydrogel-based Formulation Technology: A Breakthrough in Clinical Applications

The developing Hydrogel-based Formulation Technology has proven itself to be a very strong tool in formulating to yield versatile solutions in drug delivery, wound care, and tissue engineering. This is simply because hydrogels have unique characteristics that make them capable of living with living tissues, modulating the controlled release of drugs, and being versatile. This makes hydrogels significantly suitable for various medical applications. The above article discusses the various aspects of hydrogel technology and its role in terms of opportunities for the revolution of patient care, focusing on formulation, benefits, and utilization in clinical practice.

What is Hydrogel-based Formulation Technology?

Hydrogels are three-dimensional networks of hydrophilic polymers with remarkable water absorption and retention. Because of the water content in them, hydrogels closely mimic natural tissues, which qualify them for use in medicine. The incorporation of APIs in the three-dimensional networks to formulate targeted and controlled-release formulations of APIs is known as the Hydrogel Formulation Method. The composition and structure of hydrogels can be tailored so that various applications are possible. Such adaptability is useful for applications as diverse as wound dressings to advanced drug delivery systems.

Advantages of the Hydrogel Formulation Method

The rise in popularity of hydrogel-based formulation technology in clinical use can be attributed to several key advantages:

1. **Biocompatibility:** Hydrogels are highly biocompatible; that is, it has low cytotoxicity, so it elicits less risk of adverse reactions when applied in the body. This makes it quite significant for clinical applications such as wound healing and tissue engineering.

2. **Controlled Drug Release:** Hydrogel-based formulations may be one of the most important benefits because they can offer controlled delivery of drugs. The polymer matrix of the hydrogel can thus be engineered to release medication over a considerable period, thus making infrequent administration possible and ensuring more consistent therapeutic results.

3. **Hydration and Moisture Retention:** Hydrogels can preserve a moist environment which is essentially required for the induction of tissue repair and reduction of inflammation. This is very suitable in wound care.

4. **Customizable Properties:** Hydrogels' physical and chemical properties may be designed to change over a very broad range of values to meet specific requirements. The formulation of the polymer or the density of the cross-linking can be controlled to optimize these hydrogels to meet specific applications like localized drug delivery or repair of soft tissue.

5. **Minimally Invasive Application:** Hydrogel-based formulations may be applied to the surface of the skin or administered through injection into the body using a minimal degree of invasiveness, which is especially important and useful in wound healing and tissue regeneration areas. Conventional surgery in the same fields could be much more traumatic.

Clinical Applications of Hydrogel Formulation Method

The versatility of the Hydrogel Formulation Method has opened the door to several promising clinical applications. Here are some of the most notable areas where hydrogel technology is making an impact:

1. **Drug Delivery Systems:** Hydrogel-based formulations offer precise, sustained drug delivery, making

1. them valuable for chronic conditions like cancer and diabetes. By incorporating active pharmaceutical ingredients (APIs), these hydrogels can control drug release, maintaining therapeutic levels over time and reducing frequent dosing. In cancer treatment, hydrogels target chemotherapy to tumors, minimizing side effects, while in diabetes management, insulin can be released gradually, improving glucose control and enhancing patient outcomes. This technology enhances the effectiveness of long-term treatments.

2. **Wound Healing and Skin Regeneration:** The Hydrogel Formulation Method is highly effective for wound care, especially for chronic or non-healing wounds. Its hydrophilic properties help maintain a moist environment that promotes healing and reduces infection risk. Hydrogel dressings can be infused with therapeutic agents like antibiotics to further enhance recovery. For patients with burns, ulcers, or surgical wounds, these formulations offer a non-invasive, cooling solution that not only accelerates healing but also provides pain relief by soothing the affected area.

3. **Tissue Engineering and Regenerative Medicine:** In tissue engineering, the Hydrogel Formulation Method is key to creating scaffolds that mimic the extracellular matrix, supporting cell growth and tissue regeneration. These hydrogels are used to engineer tissues like cartilage, skin, and heart muscle. A major advancement is their role in delivering stem cells to damaged tissues, providing a protective environment that boosts cell survival and improves tissue repair, offering new treatment possibilities for degenerative diseases and injuries.

4. **Ophthalmic Applications:** Hydrogel-based formulation technology is also being used in ophthalmology, particularly for contact lenses and drug delivery to the eye. Hydrogel-based contact lenses can provide a more comfortable wearing experience due to their ability to retain moisture. Moreover, hydrogels can be used to deliver drugs directly to the eye, offering a more efficient and patient-friendly alternative to traditional eye drops, which often require frequent administration.

Challenges and Future Directions

While the Hydrogel Formulation Method holds great promise, there are several challenges that researchers and clinicians must address to fully unlock its potential.

- **Stability and Durability:** Ensuring the long-term stability and durability of hydrogel-based formulations, particularly in drug delivery systems, remains a challenge. Hydrogels can degrade over time, which may limit their effectiveness for certain applications.

- **Cost and Scalability:** The cost of producing hydrogel-based formulations, especially for personalized or highly specialized applications, can be high. Developing scalable manufacturing processes will be critical for making this technology more widely available in clinical practice.

- **Regulatory Hurdles:** As with any new medical technology, hydrogel-based formulations must undergo rigorous testing and regulatory approval before they can be used in patients. This process can be time-consuming and costly, potentially delaying the widespread adoption of the technology.

Conclusion

Hydrogel-based formulation technology can be assumed to be an advanced development in the medical world and further offers the following advantages towards the delivery of drugs, wound care, tissue engineering, and ophthalmic applications. Hydrogels have customized properties with mass potential because it is biocompatible with controlled drug release. However, the present research and development in this sector will likely help in developing even more innovative and effective solutions by using hydrogel soon. Hydrogel-based formulations could indeed prove to have great uninsurable value in advancing healthcare as the science moves forward. Such excellent technology points out what medicines could be like in the future: a given treatment tailored toward each person, with the least side effects and maximum results.

TOOLETRIES
YOUR BABY DESERVES THE BEST

THE VIKING
BEARD & HAIR OIL
TOOLETRIES
Sandalwood
Vitamin E
Beard &
Hair Oil
1 fl oz 30ml
THE
VIKING

NEWS OF THE WEE

NEW INSIGHTS INTO ASTROCYTE RESPONSE TO SPINAL CORD INJURIES AND STROKES

Recent research has shed light on the crucial role astrocytes play in responding to central nervous system (CNS) damage, particularly following spinal cord injuries or strokes. Astrocytes, star-shaped glial cells known for their support functions in the brain, have long been observed to proliferate around lesions caused by such injuries. These newly formed astrocytes create protective borders around damaged tissue, but their precise contributions to wound repair have remained unclear.

Previous studies highlighted the importance of these cells in clearing neurotransmitters and supporting the formation of synapses in healthy brains, but their role in injury recovery is gaining renewed interest. A better understanding of how astrocytes respond to tissue damage could open doors to more effective therapies for stroke and spinal cord injury patients.

Research at UCLA Sheds New Light on Astrocyte Functions

In a recent study published in Nature Neuroscience, researchers from the University of California, Los Angeles (UCLA) examined the response of astrocytes to CNS injuries in adult mice. Led by Michael Sofroniew and his team, the study found that 90% of the astrocytes forming borders around lesions originated from proliferating local astrocytes, while 10% came from oligodendrocyte progenitor cells. This discovery challenges previous assumptions that astrocytes hinder recovery, instead revealing their vital role in protecting nerve cells.

Sofroniew and his colleagues initially embarked on this research to investigate whether astrocytes prevent or support nerve cell regrowth. Their earlier findings, published in 2016 and 2018, indicated that astrocytes play a supportive role in nerve cell regeneration and tissue repair. The current study builds on that work, offering deeper insights into how astrocytes respond to damage and form neuroprotective borders.

Astrocytes as Key Players in Neuroprotection

The study reveals that these astrocytic borders serve as barriers to protect healthy neurons from inflammatory cells that infiltrate damaged areas. By surrounding these inflammatory cells, astrocytes clean up cellular debris and reduce the risk of infection. These cells, now referred to as “wound repair astrocytes,” help prevent further damage to neighboring nerve cells.

Using a combination of histological tissue sections and gene expression analysis, the researchers explored how astrocytes in the brain and spinal cord of adult mice respond to injuries. Their findings suggest that mature astrocytes de-differentiate, proliferate, and genetically reprogram themselves to support tissue repair. While astrocytes were once viewed as detrimental after traumatic injuries or strokes, this study emphasizes their neuroprotective role. The researchers also noted that astrocytic functions may become less effective with age or in certain disease conditions, highlighting the importance of further research into their role in recovery.

In conclusion, the study’s findings offer valuable insights into astrocytes’ potential in therapeutic interventions for CNS injuries, paving the way for new strategies to improve recovery following strokes and spinal cord damage.



EK

UROGEN PHARMA INITIATES PHASE 3 TRIAL FOR UGN-103 IN TREATING NON-MUSCLE INVASIVE BLADDER CANCER

Data Collection:

Healx, a pioneering U.K. startup specializing in AI-based drug discovery for rare diseases, has successfully secured $47 million in Series C funding. The funding round was co-led by Atomico from Europe and R42 from Silicon Valley. The company, founded in Cambridge in 2014 by Tim Guilliams and David Brown, has developed a unique AI platform that integrates public and proprietary data to uncover hidden links between chemical compounds and rare diseases.

Development:

The latest capital injection will accelerate Healx's Phase 2 clinical trials for its novel treatment targeting neurofibromatosis Type 1 (NF1), a genetic disorder characterized by benign tumor growth on nerves. Healx has reformulated an existing drug, now known as HLX-1502, to address NF1. The drug's development benefits from prior safety data, which enhances confidence in its reduced side effects. The trials are set to begin later this year, focusing on young adults with inoperable plexiform neurofibromas.

Key Features:

Healx's innovative approach contrasts with traditional drug discovery methods by analyzing millions of data points to identify new therapeutic connections. The company utilizes AI to match disease biology with suitable chemicals and small molecules, aiming to provide more targeted treatments with fewer side effects compared to conventional cancer therapies. The platform's success in identifying potential treatments from existing compounds highlights its unique contribution to drug discovery.

Performance:

Despite a challenging funding environment and a 45% reduction in staff last year, Healx's latest funding round demonstrates strong investor confidence in its technology. The Series C round, although lower than the previous Series B round, reflects Healx's strategic shift towards cost-effective and efficient operations. The company's focus on rare diseases and its ability to navigate economic downturns underscore its resilience and adaptability.

Significance:

Healx's progress is a testament to the growing impact of AI in drug discovery. With the pharmaceutical industry often hampered by high failure rates and lengthy development times, Healx's data-driven approach offers a promising alternative. The company's work on NF1 and other conditions exemplifies how AI can drive significant advancements in treating rare and complex diseases.

Conclusion:

As Healx prepares to launch its clinical trials and expand its presence in the U.S., its innovative approach and recent funding position it as a key player in the future of drug discovery. With a solid foundation and a clear focus on leveraging AI to tackle rare diseases, Healx is set to make a substantial impact on the field, paving the way for more effective and less burdensome treatments.



MYROBALAN THERAPEUTICS SECURES $24 MILLION TO DEVELOP GROUNDBREAKING CNS THERAPIES

Myrobalan Therapeutics, a biotechnology company focused on developing innovative neurorestorative therapies, has successfully raised $24 million in Series A financing. The funding round was spearheaded by Co-win Ventures, with participation from both new and existing investors, including Guan Zi Equity Investment, 3E Bioventures Capital, and AB Magnitude Ventures Group. The funds will be directed toward advancing Myrobalan's efforts to develop oral therapies that can repair and restore neural function in patients with degenerative central nervous system (CNS) diseases, such as multiple sclerosis (MS), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS).

Historically, CNS drug development has faced significant challenges, particularly in crossing the blood-brain barrier and creating treatments with long-term efficacy. Myrobalan aims to overcome these obstacles by developing highly selective, orally available compounds that target demyelination and neuroinflammation, two major contributors to CNS conditions. With these new therapies, Myrobalan seeks to provide hope for currently untreatable conditions that affect millions worldwide.

Innovative Approach to CNS Therapy

Myrobalan is developing a range of neurorestorative therapies, focusing on three major targets. One of these is an antagonist to G-protein coupled receptor 17 (GPR17), which promotes remyelination. Another is an inhibitor of colony-stimulating factor-1 receptor (CSF1R), which addresses both demyelination and neuroinflammation. The third is an allosteric tyrosine kinase 2 (TYK2) inhibitor, designed to reduce neuroinflammation. By targeting these mechanisms, the company aims to create treatments that address the underlying causes of various neurological conditions.

Leadership and Vision for the Future

Myrobalan's leadership team brings together extensive expertise in both research and business development. The company was co-founded by Dr. Wang in 2021, alongside renowned scientists Dr. Zhigang He from Harvard Medical School and Dr. Guoping Feng from MIT's McGovern Institute for Brain Research. This strong scientific foundation is complemented by Dr. Wang's experience in leading drug development programs from discovery to commercialization at companies like Curis and GSK. Additionally, Myrobalan has enlisted top-tier business and scientific advisors to guide the company's strategic development.

Co-founder Dr. He expressed excitement over Myrobalan's progress, noting that the company's approach to targeting key drivers of CNS diseases, such as GPR17 and TYK2, is both novel and timely. Investors, including Dr. Xin Huang from Co-win Ventures and Dr. Frank Yan from 3E Bioventures Capital, also voiced their confidence in the company's potential to revolutionize CNS treatment through its innovative research and drug design.

With its sights set on transforming the future of CNS therapy, Myrobalan Therapeutics is poised to make significant strides in developing first-in-class neurorestorative treatments that could change the lives of patients suffering from degenerative brain conditions.

UF BIOMEDICAL ENGINEER CHRISTINE SCHMIDT WAS INDUCTED INTO THE NATIONAL ACADEMY OF ENGINEERING

NATIONAL ACADEMY OF ENGINEERING
Christine E. Schmidt

University of Florida (UF) distinguished professor Christine Schmidt has been inducted into the 2024 class of the National Academy of Engineering (NAE), one of the highest honors in the field. The induction ceremony took place during the NAE's annual meeting in Washington, D.C., where Schmidt was recognized for her groundbreaking contributions to neural tissue engineering and wound healing. Her work over the past 25 years has made a significant impact on patients, particularly those suffering from nerve damage caused by injuries.

Schmidt is the Pruitt Family Endowed Chair in UF's J. Crayton Pruitt Family Department of Biomedical Engineering. Her research focuses on developing innovative materials and therapeutic systems for wound healing and the regeneration of peripheral and spinal nerves. Schmidt's work has led to the development of two widely used products: the Avance Nerve Repair graft, produced by Axogen, and the VersaWrap graft, which was developed by her startup company, Alafair Biosciences. These products have helped tens of thousands of patients, revolutionizing nerve repair treatments.

A Trailblazer in Biomedical Engineering

Schmidt's election to the NAE highlights her extraordinary contributions to the field of biomedical engineering. The NAE, which welcomed 114 newly elected members and 21 international members this year, recognizes engineers who have made pioneering advancements in research and industry. Schmidt's nerve regeneration and wound healing innovations have already benefited injured soldiers, car accident survivors, and cancer patients, making her work highly influential in both medical and scientific communities.

"Dr. Schmidt has forged a path toward nerve regeneration and wound healing that is already having a remarkable impact," said Forrest Masters, Ph.D., interim dean of UF's Herbert Wertheim College of Engineering. "We are proud to be her colleagues and congratulate her on this tremendous accomplishment." Masters emphasized how Schmidt's work has redefined nerve repair, providing new hope for patients in need of advanced medical solutions.

Leadership and Legacy at the University of Florida

Schmidt joined UF in 2013 after serving at the University of Texas at Austin. During her time at UF, she led the J. Crayton Pruitt Family Department of Biomedical Engineering for over a decade, significantly advancing interdisciplinary research and promoting the application of engineering solutions to biomedical challenges. Under her leadership, the department expanded its national visibility and impact, leading to more opportunities for translating scientific discoveries into real-world medical applications.

Reflecting on her NAE induction, Schmidt expressed gratitude to her colleagues, collaborators, and students, attributing the honor to the support and hard work of her team. "This recognition reflects the dedication and hard work of my incredible team, collaborators, and students, as well as the supportive environment at the University of Florida," she said. Schmidt added that she looks forward to continuing her work in biomedical engineering, aiming to push the boundaries of science and innovation to further improve patient outcomes.

With her election to the National Academy of Engineering, Schmidt solidifies her role as a leader in biomedical innovation, committed to advancing science and fostering the next generation of bioengineers.

COBH
SAFEGUARDING LIFE ON EARTH


DAMAGED IN
DAMAGED OUT

Spinal Cord Repair:

Advances and Challenges in Treating Spinal Injuries

The spinal cord is an important part of the human body, if this part is damaged one might lose their sensory function, and suffer paralysis, and other severe complications. The spinal cord repair is an important point in the medical industry. Through this blog, we have tried to cover every aspect of a spinal cord injury and its repair.

What is Spinal Cord Repair?

It means a patient needs long-term care to manage the damaged spine. The doctors identify the actual cause of a damaged spine by taking out X-rays, CT scans, and MRIs. Long-term care includes rehabilitation, medications, and the use of modern technologies like stimulation devices to improve the patient's mobility and reduce their dependency on others.

Understanding Spinal Cord Injuries

A spinal cord injury takes place when trauma damages the spinal cord, interrupting the brain's ability to send signals to the rest of the body. These injuries can be caused by a variety of incidents such as car accidents, falls, sports injuries, or violence. The severity of a spinal cord injury depends on its location and extent. Injuries higher up on the spinal cord tend to result in more extensive paralysis, while injuries lower down may affect fewer functions.

The immediate effects of a spinal cord injury often include loss of mobility, sensory loss, bladder and bowel dysfunction, and chronic pain. These symptoms can last a lifetime without appropriate treatment. By repairing the damaged spinal cord one can get back functions as much as possible

Current Treatment Options for Spinal Cord Injuries

Currently, there is no definitive cure for spinal cord injuries, but various treatments can manage symptoms and help prevent further damage. Traditional methods of treating spinal cord injuries include physical therapy, medications, and surgery. These treatments are primarily focused on stabilizing the injury, reducing inflammation, and preventing complications like infections or further trauma.

Surgery: In cases of spinal cord injury, surgery is often performed to relieve pressure, stabilize the spine, or remove fragments of bone that may be pressing on the spinal cord. However, while surgery can help stabilize the injury, it doesn't lead to significant spinal cord repair in itself.

Rehabilitation and Physical Therapy: After initial treatment, physical therapy plays a critical role in helping patients regain strength and independence. Physical therapy focuses on improving mobility, muscle strength, and functional capabilities.

Medications: Anti-inflammatory drugs and other medications can reduce swelling and secondary damage after the initial injury. For example, high doses of steroids like methylprednisolone may be administered to control inflammation and limit further damage.

Despite these approaches, full spinal cord repair remains mysterious, leading to continued research into innovative treatments.

Cutting-edge research and Advancements

In recent years, spinal cord repair has seen several innovative discoveries in the medical field. Researchers are exploring new methods such as stem cell therapy, nerve regeneration, and neuroplasticity to promote healing after a spinal cord injury. These advances aim not only to manage symptoms but also to reverse some of the damage done to the spinal cord.

1. Stem Cell Therapy

One of the most prominent areas of research in spinal cord repair involves the use of stem cells. Stem cells can develop into various cell types, including neurons, which are necessary for spinal cord function. Scientists believe that stem cells can help regenerate damaged nerve cells, bridge gaps in the spinal cord, and improve body functions.

Several clinical trials are underway to test the effectiveness of stem cell treatments for spinal cord repair. Early results have shown that stem cell therapy may improve motor function and reduce inflammation around the injury site. However, more research is needed to understand the use of stem cells in repairing the spinal cord.

2. Neuroplasticity and Neural Regeneration

Neuroplasticity refers to the brain and spinal cord's ability to rewire itself, forming new neural connections in response to injury. Researchers are investigating ways to harness this natural process to aid in spinal cord repair. By stimulating neuroplasticity, scientists hope to encourage the remaining healthy nerves in the spinal cord to take over the functions of damaged nerves.

approach focuses on regenerating the damaged nerves in the spinal cord using techniques such as nerve grafts, gene therapy, and electrical stimulation. The goal is to restore the nerve pathways that control movement and sensation.

3. Biomaterials and Scaffold Implants

Biomaterials are another innovative approach in the quest for spinal cord repair. Researchers are developing biomaterial scaffolds that can be implanted into the damaged area of the spinal cord. These scaffolds provide a structure for new nerve cells to grow, bridging the gap between damaged areas. Additionally, biomaterials can be loaded with growth factors that increase tissue regeneration.

Preclinical studies have demonstrated that these scaffold implants may improve nerve regeneration and motor recovery in animal models. This technology is in the experimental phase but has a great scope.

4. Electrical Stimulation

Electrical stimulation is a technique that involves sending controlled electrical signals to the spinal cord to stimulate nerve activity. This method has shown some success in helping patients with incomplete spinal cord injuries regain partial movement and control. By stimulating specific areas of the spinal cord, electrical signals can help bypass damaged nerves and restore function.

Many patients experience better mobility through electrical stimulation devices, which promises us more innovative applications. However, like many emerging therapies, more research is needed to understand, innovate, and use the technologies effectively.

Challenges

While advancements in spinal cord repair are developing, there are still many challenges to overcome. One major obstacle is the complexity of the spinal cord itself. The spinal cord consists of millions of nerve cells, each with unique functions, making it difficult to repair without affecting other parts of the body.

Another challenge is the body’s immune response to injury. When the spinal cord is damaged, the body’s natural defense mechanism creates scar tissue around the injury site. This scar tissue can prevent nerve regeneration and block treatments from reaching the damaged area.

Additionally, many of the treatments currently being explored are still in experimental stages. Clinical trials for spinal cord repair are ongoing, but the proven success of the solutions will take time to spread across the globe.

Future

Though there are several challenges, the future of advancements in technology to repair the spinal cord has a lot of potential. The research in stem cells, neuroplasticity, and biomaterials gives us hope that the cure for spinal cord injuries may become a reality. With more advancements on the horizon, the next decade may bring even more solutions to repair the spinal cord.

Key Takeaways

Spinal Cord Injuries are difficult and life-changing events in an individual’s life. Thus there is so much research being done in the field of spinal cord injuries. From stem cell therapy to neuroplasticity to biomaterials and electrical stimulation, scientists are working relentlessly to develop treatments that can restore function in an individual which will provide them with a good quality of life.



Reminder

You deserve a Bright Smile today

Okay

Your Destination for Comprehensive and Compassionate
Dental Care in the Heart of Egypt and Beyond.

www.capitaldental.clinic

THE LIFESCIENCES MAGAZINE